Please login to the form below
progressive supranuclear palsy
This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.
Biogen grows in Q2, but Spinraza performance a concern
Biogen has a number of significant clinical readouts over the next 18 months, but many of these remain high risk, such as the phase 3 trial of BIIB092 in progressive supranuclear ... palsy. One big binary decision awaiting the firm is a challenge
Latest news
-
Spinraza keeps Biogen afloat as Tecfidra stalls
He adds: “By the end of 2020 we expect readouts across our clinical programmes in MS, progressive supranuclear palsy, ALS, Parkinson’s disease, pain, cognitive impairment associated with schizophrenia, epilepsy, stroke, ... Trial results of
-
Spinraza lifts Biogen ahead of Alzheimer’s data
enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.
-
Celgene bulks up pipeline again with $2.1bn Prothena deal
The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
-
AbbVie takes anti-tau drug into phase II for Alzheimer's
drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to
-
AbbVie and C2N take tau antibody into clinic
Treatment being assessed for a progressive neurodegenerative disorder. AbbVie and partner C2N have started clinical trials of an antibody targeting tau proteins that has just been granted orphan drug status by ... The first-in-class therapy - called
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch - May 2017
BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
-
Deal Watch table for April 2014
750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Cello Health
Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
